Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dacomitinib Bests Gefitinib in EGFR-Mutant NSCLC

June 6th 2017

Dacomitinib, a second-generation EGFR inhibitor, reduced the risk of disease progression by more than 40% and resulted in an average 6.5-month improvement in response duration compared with gefitinib (Iressa) as a first-line treatment for patients with advanced, EGFR-mutant non–small cell lung cancer.

Nintedanib Chemo Combo Promising for Malignant Mesothelioma

June 5th 2017

Frontline treatment with nintedanib plus pemetrexed and cisplatin improved progression-free survival by 3.7 months for chemotherapy-naive patients with malignant pleural mesothelioma, according to data reported at the 2017 ASCO Annual Meeting.

Nivolumab Alone or With Ipilimumab Controls Disease, Extends Survival, in Mesothelioma

June 5th 2017

Nivolumab as monotherapy or in combination with ipilimumab may present a new second- or third-line treatment option for patients with malignant pleural mesothelioma, based on preliminary findings from a phase II trial where nivolumab alone or in the combination improved disease control and prolonged survival in patients with this rare but aggressive cancer.

Alectinib Delayed Progression, Reduced Risk for Death by 53% in ALK+ NSCLC

June 5th 2017

In patients with ALK-positive non-small cell lung cancer, the second-generation TKI inhibitor alectinib (Alecensa) delayed progression by an additional 15 months compared with the standard-of-care crizotinib (Xalkori).

Pembrolizumab/Chemo PFS Benefit in NSCLC Sustained With Longer Follow-Up

June 3rd 2017

The frontline combination of pembrolizumab, pemetrexed, and carboplatin reduced the risk of progression or death by 50% and nearly doubled objective response rates compared with chemotherapy alone for patients with advanced non-squamous NSCLC.

Dr. Papadimitrakopoulou on Treatment Options for EGFR-Mutant NSCLC

June 2nd 2017

Vassiliki A. Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses treatment options for patients with EGFR-mutant non-small cell lung cancer (NSCLC).

Dr. Heymach on the Significance of Nivolumab for Lung Cancer

June 2nd 2017

John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the significance of nivolumab (Opdivo) for patients with lung cancer.

Best Initial Treatment Strategies for EGFR-Mutant Lung Cancer

June 1st 2017

This review will focus on current therapies used in the first-line setting for advanced EGFR mutation positive non–small cell lung cancer (NSCLC) followed by emerging data that may lead to a transition in the choice for initial therapy in these patients.

Marine-Derived Drug Anchors Chemo Regimen in SCLC Trial

June 1st 2017

Lurbinectedin (PM01183 or PM1183), a transcription inhibitor that induces DNA double-strand breaks, is being combined with doxorubicin in a phase III trial for patients with recurrent small cell lung cancer in the hopes of providing a superior option to the current standard-of-care second-line chemotherapy.

NICE Makes Pembrolizumab Available in Frontline NSCLC Through Cancer Drugs Fund

June 1st 2017

The UK’s National Institute for Health and Care Excellence will allow first-line use of pembrolizumab (Keytruda) for non–small cell lung cancer as part of the Cancer Drugs Fund.

Dr. Farago on Opportunities to Investigate Biomarkers for Small Cell Lung Cancer

May 31st 2017

Anna Farago, MD, PhD, Massachusetts General Hospital Cancer Center, instructor of Medicine at Harvard Medical School, discusses opportunities for the development of biomarkers for patients with small cell lung cancer (SCLC).

Surgery Remains Imperative in Lung Cancer Treatment

May 31st 2017

Eric Lambright, MD, discusses the ongoing role of surgery in the treatment of patients with lung cancer.

ASCO 2017: Oncology Leaders Pick Their Top Abstracts

May 30th 2017

Key opinion leaders spoke with OncLive to share the top-5 abstracts they find to be the most exciting and/or potentially practice-changing across breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, hematologic malignancies, and supportive care being presented at the 2017 ASCO Annual Meeting.

Modern Biopsy Techniques Changing the Scope of Lung Cancer Diagnoses

May 30th 2017

Susan Garwood, MD, discusses biopsy advancements and the future of techniques in lung cancer.

Immunotherapy Gains Frontline Foothold in NSCLC

May 29th 2017

Less than 2 years after checkpoint blockade immunotherapy first became available for patients with non-small cell lung cancer, the PD-1 inhibitor pembrolizumab is poised to reshape the treatment paradigm for previously untreated individuals without molecular mutations.

Dr. Johnson on the Future of Immunotherapy in Lung Cancer

May 27th 2017

Melissa L. Johnson, MD, medical oncologist, Sarah Cannon Research Institute, discusses potential immunotherapy regimens for patients with lung cancer.

Dr. West on FDA Approval of Frontline Ceritinib for Frontline ALK+ NSCLC

May 27th 2017

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the FDA approval of ceritinib (Zykadia) as a first-line treatment for patients with ALK-positive, metastatic non–small cell lung cancer (NSCLC).

FDA Approves Ceritinib for Frontline ALK+ NSCLC

May 26th 2017

The FDA has approved ceritinib (Zykadia) for the treatment of patients with ALK-positive, metastatic non–small cell lung cancer.

Ceritinib Recommended for EU Approval in Frontline ALK+ NSCLC

May 19th 2017

The EMA’s Committee for Medicinal Products for Human Use has recommended approval of ceritinib (Zykadia) for the treatment of patients with ALK-positive, metastatic non–small cell lung cancer, according to Novartis, the manufacturer of the second-generation ALK inhibitor.

Adjuvant Gefitinib Delays Recurrence in EGFR+ NSCLC

May 18th 2017

Adjuvant gefitinib reduced the risk of disease recurrence by 40% versus standard chemotherapy in patients with EGFR-positive non–small cell lung cancer, study reports.